Skip to main content
SpringerLink
Log in

Aldosterone-Producing Adrenocortical Carcinoma

  • Chapter
  • First Online:
Adrenocortical Carcinoma

  • 635 Accesses

Abstract

In 1955 Conn described the syndrome of primary hyperaldosteronism (PHA) [1], which has come to be known as “Conn’s Syndrome” [2]. PHA is a group of disorders in which aldosterone production is inappropriately high, relatively autonomous from the renin-angiotensin system, and nonsuppressible by sodium loading. Such inappropriate production of aldosterone causes cardiovascular damage, suppression of plasma renin, hypertension, sodium retention, and potassium excretion that if prolonged and severe may lead to hypokalemia. PHA is commonly caused by adenoma (35%), bilateral adrenal hyperplasia (60%), or (rarely) by aldosterone producing adrenocortical carcinoma (APAC) (<1%) (Table 27.1) [3]. The first APAC was reported in 1955 by Foye and Feichtmeir [4] shortly after Conn’s original report. Aldosterone hypersecretion in adrenocortical carcinoma (ACC) is rare with only 58 patients being reported in a recent review [5]. The reported numbers of APAC amongst ACCs vary significantly. In one large series of ACCs, only 2.5% had developed hyperaldosteronism [6]. In a single center analysis on ACCs, which were subjected to operative management at the Mayo Clnic, the portion of APACs was 11%. Conversely, it has been estimated that hyperaldosteronism is due to APAC in only 1% of patients with PHA [7].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Conn JW (1955) Primary aldosteronism. J Lab Clin Med 45:661–664

    CAS  PubMed  Google Scholar 

  2. Hajjar RH et al (1975) Adrenal cortical carcinoma- a study of 32 cases. Cancer 35:549–554

    Article  CAS  PubMed  Google Scholar 

  3. Funder JW et al (2008) Endocrine society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab Sep 93(9):3266–3281

    Article  CAS  Google Scholar 

  4. Foye LV Jr, Feichtmeir TV (1955) Adrenal cortical carcinoma producing solely mineralocorticoid effect. Am J Med 19:966–975

    Article  PubMed  Google Scholar 

  5. Seccia TM et al (2005) Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn’s syndrome with an ominous clinical course. Endocr Relat Cancer 12:149–159

    Article  PubMed  Google Scholar 

  6. Ng L, Libertino JM (2003) Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 169:5–11

    Article  PubMed  Google Scholar 

  7. Mattsson C, Young WF Jr (2006) Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2:198–208

    Article  CAS  PubMed  Google Scholar 

  8. Messer CK et al (2007) Concomitant secretion of glucocorticoid, androgens, and mineralcorticoid by an adrenocortical carcinoma: case report and review of literature. Endocr Pract. Jul–Aug 13(4):408–412

    Google Scholar 

  9. Hogan TF et al (1980) A clinical and pathological study of adrenal carcinoma. Cancer 45:2880–2883

    Article  CAS  PubMed  Google Scholar 

  10. Libè R et al (2007) Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14(1):13–28

    Article  PubMed  Google Scholar 

  11. Lipsett MB et al (1963) Clinical and pathophysiologic aspects of adrenocortical carcinoma. Am J Med 35:374–383

    Article  CAS  PubMed  Google Scholar 

  12. Salassa RM et al (1975) Primary aldosteronism and malignant adrenocortical neoplasia. Trans Am Clin Clin Assoc 86:163–169

    CAS  Google Scholar 

  13. Levine DS et al (1984) Isolated production of aldosterone by a malignant adrenal carcinoma yale. J Biol Med 57(6):833–841

    CAS  Google Scholar 

  14. Alterman SL et al (1969) Primary adrenocortical carcinoma causing aldosteronism. Cancer 24:602–609

    Article  CAS  PubMed  Google Scholar 

  15. Brooks RV et al (1957) Potassium deficiency of renal and adrenal origin. Am J Med 23:391–407

    Article  CAS  PubMed  Google Scholar 

  16. Crane MG et al (1965) Primary aldosteronism due to adrenal carcinoma. Ann Intern Med 63:494–503

    CAS  PubMed  Google Scholar 

  17. Feldman S, Ravera JJ (1961) Arterial hypertension caused by a primary malignant adrenocortical tumor. Thorax Dec 10:284–288

    CAS  Google Scholar 

  18. Knapton PJ (1965) Hypokalemic alkalosis in adrenal carcinoma. Lancet ii:346

    Google Scholar 

  19. Santander S et al (1965) Case of probable mineralcorticoid excess without hypercortisolism due to carcinoma of the adrenal cortex. J Clin Endocrinol 25:1429–1435

    Article  CAS  Google Scholar 

  20. Zimmerman B et al (1959) Physiologic and surgical problems in the management of primary aldosteronism. Ann Surg 150:653–664

    Article  Google Scholar 

  21. Abma EM et al (2008) Malignant aldosterone-producing adrenal tumor: reoccurrence with glucocorticoid excess without hyperaldosteronism. Neth J Med. Jun 66(6):252–255

    CAS  Google Scholar 

  22. Barzon L et al (1997) Adrenocortical carcinoma: experience in 45 patients. Oncology 54:490–496

    Article  CAS  PubMed  Google Scholar 

  23. Hisamatsu H et al (2002) Adrenocortical carcinoma with primary aldosteronism associated with Cushing syndrome during recurrence. BJU Int 90:971–972

    Article  CAS  PubMed  Google Scholar 

  24. Lack EE Adrenal cortical carcinoma. In: Lack EE (ed) Tumors of the adrenal gland and extradrenal paraganglia. Armed Forces Institute of Pathology, Washington, DC, pp 123–147

    Google Scholar 

  25. Ehrlich EN et al (1963) J Clin Endocrinol Metab 23:358

    Article  CAS  Google Scholar 

  26. Todesco S et al (1975) Primary Aldosteronism due to a malignant ovarian tumor. JCEM 41(5):809–819

    CAS  PubMed  Google Scholar 

  27. Rossi GP et al (2000) A thoracic mass with hypertension and hypokalaemia. Lancet 356(9241):1570

    Article  CAS  PubMed  Google Scholar 

  28. Flanagan MJ, McDonald JH (1967) Heterotopic adrenocortical adenoma producing primary aldosteronism. J Urol 98:133–139

    CAS  PubMed  Google Scholar 

  29. Zubair M et al (2009) Transgenic expression of Ad4BP/SF-1 in fetal adrenal progenitor cells leads to ectopic adrenal formation. Mol Endocrinol 23:1657–1667

    Article  CAS  PubMed  Google Scholar 

  30. Gicquel C, Le Bouc Y (1997) Molecular markers for malignancy in adrenocortical tumors. Horm Res 47(4–6):269–272

    Article  CAS  PubMed  Google Scholar 

  31. Suzuki T et al (1992b) Discerning malignancy in human adrenocortical neoplasms: utility of DNA flow cytometry and immunohistochemistry. Mod Pathol May 5(3): 224–231

    CAS  Google Scholar 

  32. Ghnassia JP et al (1993) Adrenal cortical tumors. Prognostic evaluation of a series of 12 cases using anti-PCNA antibodies. Ann Pathol 13(5):312–316

    CAS  PubMed  Google Scholar 

  33. Reincke M et al (1994) p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab Mar 78(3):790–794

    Article  CAS  Google Scholar 

  34. Sasano H et al (1995) Transcription factor adrenal 4 binding protein as a marker of adrenocortical malignancy. Hum Pathol Oct 26(10):1154–1156

    Article  CAS  Google Scholar 

  35. Mannelli M et al (2000) Telomerase activity is significantly enhanced in malignant adrenocortical tumors in comparison to benign adrenocortical adenomas. J Clin Endocrinol Metab Jan 85(1):468–470

    Article  CAS  Google Scholar 

  36. Greathouse DJ et al (1984) Pure primary hyperaldosteronism due to adrenal cortical carcinoma. Am J Med Jun 76(6):1132–1136

    Article  CAS  Google Scholar 

  37. Young WF Jr (1997) Pheochromocytoma and primary aldosteronism: diagnostic approaches. Endocrinol Metab Clin North Am Dec 26(4):801–827

    Article  Google Scholar 

  38. Deckers S et al (1999) Peritoneal carcinomatosis following laparoscopic resection of an adrenocortical tumor causing primary hyperaldosteronism. Horm Res 52(2):97–100

    Article  CAS  PubMed  Google Scholar 

  39. Dixon AN, Bing RF (2001) Two cases of adrenocortical carcinoma presenting as Conn’s syndrome. J Hum Hypertens Jan 15(1):75–79

    Article  CAS  Google Scholar 

  40. Weingärtner K et al (1995) Isolated clinical syndrome of primary aldosteronism in a patient with adrenocortical carcinoma. Case report and review of the literature. Urol Int 55(4):232–235

    Google Scholar 

  41. Taylor W et al (1997) Adrenal carcinoma presenting as Conn’s syndrome. Aust N Z J Med Apr 27(2):201–202

    CAS  Google Scholar 

  42. Ali AE, Raphael SJ (2007) Funchonal Oncocytic adrenocortical carcinoma. Endocr Pathol Fall 18(3):187–189

    Article  Google Scholar 

  43. Schulick RD, Brennan MF (1999) Adrenocortical carcinoma. World J Urol Feb 17(1):26–34

    Article  CAS  Google Scholar 

  44. Cobb W et al (2005) Laparoscopic adrenalectomy for malignancy. Am J Surg 189:405–411

    Article  PubMed  Google Scholar 

  45. Paton BL et al (2006) Outcomes of adrenal cortical carcinoma in the United States. Surgery 140:914–920

    Article  PubMed  Google Scholar 

  46. Biglieri EG et al (1966) Postoperative studies of adrenal function in primary aldosteronism. J Clin Endocr 26:553–558

    Article  CAS  PubMed  Google Scholar 

  47. Kendrick ML et al (2002) Aldosterone-secreting adrenocortical carcinomas are associated with unique operative risks and outcomes. Surgery 132:1008–1011

    Article  PubMed  Google Scholar 

  48. Skogseid B et al (2008) Experience from an ongoing phase III study: FIRM-ACT. Abstract book of the 2nd annual international adrenal cancer symposium: clinical and basic science. March 14–15

    Google Scholar 

  49. Terzolo M et al (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356:2372–2380

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Department of Medical and Surgical Sciences, University of Padua, Via Ospedale, 105, Padua, Italy

    Anna Patalano

  2. Division of Endocrinology, Department of Medical and Surgical Sciences, University of Padua, Via Ospedale 105, 35128, Padova, Italy

    Maria V. Cicala & Franco Mantero

Authors
  1. Anna Patalano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria V. Cicala
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Franco Mantero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna Patalano .

Editor information

Editors and Affiliations

  1. Zina Pitcher Place 109, Ann Arbor, 48109-2200, Michigan, USA

    Gary D. Hammer

  2. Dept. Internal Medicine, Div. Pulmonary & Critical Care Medicine, University of Michigan Health System, Zina Pitcher Place 109, Ann Arbor, 48109-2200, Michigan, USA

    Tobias Else

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Patalano, A., Cicala, M.V., Mantero, F. (2009). Aldosterone-Producing Adrenocortical Carcinoma. In: Hammer, G., Else, T. (eds) Adrenocortical Carcinoma. Springer, New York, NY. https://doi.org/10.1007/978-0-387-77236-3_27

Download citation

Publish with us

Policies and ethics

Search

Navigation